New tools and innovative developments in technology have played a key role in the field of medicine. One such technology that is enabling great amount of efficiencies in pharmaceutical development is mobile phones. This technology, which has revolutionised sharing of information digitally, has wide applications in the pharmaceutical industry.
Biotechnology today has evolved from a science to impacting human life in more ways than one. Paradigm shifts, dynamic changes and interplay between West and East in terms of capital innovation to bring about the much needed sync between biotech research and biobusiness have opened innumerable possibilities.
Pharma research requires access to materials from today's gold standard of medical care to discover the next generation of therapeutics. This need is increasing in the upcoming area of personalized medicine. Collaboration with MDs and their ethic committees is crucial to built up a pharma research biobank, as is the willingness of patients to donate samples. Success in this strategic area of operations requires multi-dimensional skills.
"Biosimilars will eventually bring down the cost of biological medicines and in doing so will expand the market", Cecil Nick, Principal Consultant, PAREXEL Consulting, UK.
An innovative approach to overcome the risk factors and stem the failure of drugs which are often developed on a trial and error basis, the concept of personalised medicine comes with its own share of benefits and challenges.
Caught in the “Innovation Deficiency Syndrome”, and under serious pressure to compensate declining revenue streams from saturated markets, soon-to-expire / already expired blockbusters, pharma companies are increasingly partnering with biotechs to help reduce their losses.
Natural products-based drug discovery is gaining prominence once again.
Globalisation, free trade, investment, entrepreneurial zeal are all set to metamorphose Indian pharma companies that were once labelled as the copy cat drug makers into discovery-led firms.
The Asian pharmaceutical industry presents a two-fold opportunity to the troubled world of the global pharma industry.
Welcome to the latest edition of Pharma Focus Asia. The issue of outsourcing in the pharmaceutical sector has been a hot topic for discussion recently, particularly now that the US Congress is considering reforming patent law. The new legislation could have significant repercussions for firms that use the USA as part of their business strategy, especially as pharmaceutical and biotechnology companies now outsource at almost every stage in the value chain.